Brivaracetam-Associated Rhabdomyolysis Requiring Renal Replacement Therapy: A Case Report and Review of the Literature.
| Autor: | Alok K; Neurocritical Care, Northwell Health, Manhasset, USA., Lin A; Pharmacy, Neurocritical Care, Northwell Health, Manhassett, USA., Rahman Dematteo C; Neurocritical Care, Northwell Health, Manhasset, USA., Abrar H; Internal Medicine, Northwell Health, Manhasset, USA., Levy Z; Neurocritical Care, Northwell Health, Manhasset, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Apr 13; Vol. 16 (4), pp. e58183. Date of Electronic Publication: 2024 Apr 13 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.58183 |
| Abstrakt: | Rhabdomyolysis is a rare adverse reaction that has a previously established association with levetiracetam use, which selectively binds the synaptic vesicle glycoprotein 2A (SV2A). Its structural analogue, brivaracetam, is a new third-generation antiseizure medication that has a higher affinity for SV2A, and current data suggests it provides a more favorable adverse event profile. Here, however, we report a case of rhabdomyolysis requiring dialysis in which serum creatine kinase level increased rapidly for several days until brivaracetam was discontinued. The delayed creatine kinase peak, rapid decline upon discontinuation of brivaracetam, and prior association of rhabdomyolysis with levetiracetam strongly suggest a causal relationship. To date, there are three reported cases of brivaracetam-associated rhabdomyolysis in the food and drugs administration adverse event reporting system (FAERS). Despite its favorable side effects profile, the use of brivaracetam may be associated with life-threatening rhabdomyolysis. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Alok et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|